These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Papaverine plus prostaglandin E1 versus prostaglandin E1 alone for intracorporeal injection therapy.
    Author: Zaher TF.
    Journal: Int Urol Nephrol; 1998; 30(2):193-6. PubMed ID: 9607891.
    Abstract:
    PURPOSE: A study comparing intracorporeal injection of prostaglandin E1 (one-drug solution) and papaverine plus prostaglandin E1 (2-drug solution) for treatment of impotence. MATERIALS AND METHODS: A total of 100 impotent patients had intracorporeal injections of the one-drug and 2-drug solution alternatively in 3 sessions. The quality and duration of erections were assessed. RESULTS: Seventy-five per cent of the patients developed full erection with the 2-drug solution compared to 50% with the one-drug solution. The average duration of erections was 60 minutes and 45 minutes, respectively. The complication rate was higher for the 2-drug solution. CONCLUSION: Papaverine plus prostaglandin E1 is superior to prostaglandin E1 alone for treatment of impotence, but has a higher rate of complications. Intracavemous injection of vasoactive drugs is a very effective and important way for treatment of impotence. Papaverine plus prostaglandin E1 had been used for treatment of impotence alone or combined. A blind study was done to compare efficiency and complication rates of intracavemous injection of papaverine plus prostaglandin E1 (2-drug solution) with prostaglandin E1 alone.
    [Abstract] [Full Text] [Related] [New Search]